Room-Temperature Lipid Nanoparticle Formulation for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lipid nanoparticle-based nucleic acid therapeutics require cold storage, which is impractical for widespread distribution, especially in developing countries lacking cold chain facilities, and lyophilized formulations are susceptible to medication errors.
Innovation Solution
A lipid nanoparticle composition comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid, which can be stored at room temperature and does not require reconstitution before administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipid nanoparticle formulations are stored at frozen temperatures to maintain stability, then the therapeutic efficacy is preserved, but the storage and distribution complexity increases significantly
Solution Approach 1:
The patent changes the storage temperature parameter from frozen (-70°C or -20°C) to room temperature (20-25°C), fundamentally altering the storage conditions. This is achieved through specific formulation composition including ionizable polymers, cationic lipids, phospholipids, sterols, and PEG-lipids in optimized ratios, allowing the LNP to maintain stability without freezing while dramatically simplifying the cold chain infrastructure requirements
Solution Approach 2:
The patent employs a composite lipid nanoparticle formulation combining multiple components: ionizable polymer (1-25 mol%), cationic lipid (25-50 mol%), phospholipid (10-30 mol%), sterol (10-30 mol%), and PEG-lipid (0.1-5 mol%). This composite structure provides both room temperature stability and effective nucleic acid delivery, resolving the contradiction between maintaining efficacy and reducing storage complexity
2Reliability
If lyophilized formulations are used to improve stability, then the storage conditions are improved, but the risk of medication errors increases due to reconstitution requirements
Solution Approach 1:
The patent extracts and eliminates the reconstitution step entirely by formulating the LNP to be stable in its liquid state at room temperature. Instead of requiring conversion from lyophilized powder to liquid, the formulation is designed to maintain stability and efficacy directly in injectable form, removing the potential for medication errors associated with reconstitution while preserving storage stability
Solution Approach 2:
The formulation is designed to be self-stable at room temperature without requiring any additional processing or reconstitution steps. The LNP composition inherently maintains its stability and functionality in the final dosage form, eliminating the need for manual reconstitution operations and reducing the complexity of administration procedures
3Reliability
If cold chain facilities are required for storage and transport, then the therapeutic stability is maintained, but the accessibility and distribution reach are limited
Solution Approach 1:
The patent fundamentally changes the storage temperature parameter from frozen to room temperature, enabling distribution in regions without cold chain infrastructure. The specific formulation composition allows the LNP to maintain therapeutic stability at 20-25°C, dramatically expanding geographic and logistical accessibility while preserving efficacy
Solution Approach 2:
The room temperature stable LNP formulation achieves universal applicability across diverse settings - from well-equipped medical centers to remote areas with limited infrastructure. The single formulation design serves multiple distribution scenarios without requiring different storage conditions, enhancing versatility and accessibility globally
Data Source
AI summary
The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.